Suppr超能文献

我们如何评估临床试验的结果:最小临床重要差异(MCID)方法。

How can we assess outcomes of clinical trials: the MCID approach.

作者信息

Make Barry

机构信息

Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA.

出版信息

COPD. 2007 Sep;4(3):191-4. doi: 10.1080/15412550701471231.

Abstract

Interpreting changes in outcomes of clinical trials in chronic obstructive pulmonary disease should be viewed from a broader perspective than only the statistical significance of the findings. The minimal clinical difference in outcome measures provides a conceptual framework to assist in clinical trial interpretation and a methodology to assess the clinical relevance of study results. Use of distribution-based techniques, comparison with other external measures, and opinions from experts, clinicians and patients can assist in minimal clinically important difference development. Although the minimal clinically important difference has been suggested for a wide range of outcomes of importance in chronic obstructive pulmonary disease, many have not been subjected to rigorous analysis. For newer tools such as activity monitors and questionnaires and measures not widely employed such as laboratory-based exercise tests, minimal clinically important differences remain to be determined.

摘要

解读慢性阻塞性肺疾病临床试验结果的变化,应从比仅研究结果的统计学意义更广泛的角度来看待。结局指标的最小临床差异提供了一个概念框架,有助于解释临床试验结果,并提供一种评估研究结果临床相关性的方法。使用基于分布的技术、与其他外部指标进行比较以及专家、临床医生和患者的意见,有助于确定最小临床重要差异。尽管对于慢性阻塞性肺疾病中一系列重要结局已经提出了最小临床重要差异,但许多差异尚未经过严格分析。对于诸如活动监测器和问卷等较新的工具,以及诸如基于实验室的运动测试等未广泛应用的指标,最小临床重要差异仍有待确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验